Home/Sound Pharmaceuticals/Jonathan Kil, MD

JK

Jonathan Kil, MD

CEO & Chief Medical Officer

Sound Pharmaceuticals

Therapeutic Areas

Hearing Loss Tinnitus Meniere's Disease Ototoxicity

Sound Pharmaceuticals Pipeline

Drug	Indication	Phase
SPI-1005	Hearing loss in Meniere's Disease	Phase 2
Regeneration Program	Hearing restoration	Pre-clinical

Leadership Team at Sound Pharmaceuticals

John Sullivan, CPA

Chief Financial Officer

G. Michael Wall, PhD

Vice President, Pharmaceutical Development

View full Sound Pharmaceuticals profile